Doctors seek right dose to shield vulnerable transplant patients from deadly fungus
NCT ID NCT06541067
Summary
This study aims to find out if a drug called posaconazole is given at a high enough dose to prevent serious fungal infections in patients who have received a stem cell transplant. It will enroll 30 adult patients with blood cancers who are at high risk for these infections. Researchers will closely monitor drug levels in the blood to see if the current dosing is effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Nantes
RECRUITINGNantes, France, 44000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.